Drugs News and Research

RSS

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

FDA grants priority review status for Isotechnika Pharma's voclosporin

Isotechnika Pharma Inc. today announced that the New Drug Application (NDA) for the Company's next generation calcineurin inhibitor, voclosporin, has been accepted for priority review as filed by the U.S. Food and Drug Administration (FDA). The application was submitted by Isotechnika's partner, Lux Biosciences, Inc.

31 Mar 2010

Patients switching to Victoza experience further reductions in A1c and weight loss

Diabetes Care published online the results of the Novo Nordisk LEAD™ 6 extension study, which evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. Results show that when added to oral antidiabetes drugs, patients who switched from exenatide to Victoza experienced further reductions in A1c and weight loss.

31 Mar 2010

State roundup: Romney on Mass. care, Kansas Rx costs, Colorado insurance costs

The Boston Globe, on former Mass. Gov. Mitt Romney's reaction to the new federal health law: "The former governor, who has been mentioned as a possible candidate again for president in 2012, had labeled Obama's bill 'unhealthy for America' and has called for its repeal, even as conservative critics say it was modeled on Romney's policy."

31 Mar 2010

Close-ups on how the health overhaul gives and takes away

"An association representing 300 large corporations urged President Obama and Congress on Monday to repeal a provision of the health care overhaul that prompted AT&T, Caterpillar and other companies to announce substantial charges for the current quarter."

31 Mar 2010

Women, diabetics, dementia patients most likely to fall in 'doughnut hole'; Reform seeks to close coverage gap

Among elderly Americans, women and those with diabetes and dementia are most likely to find themselves in the Medicare Part D drug plan 'doughnut hole,' the coverage gap that occurs after a beneficiary has reached the annual coverage limit but hasn't spent enough on drugs to qualify for catastrophic coverage.

31 Mar 2010

Access Pharmaceuticals, bioRASI sign collaborative agreement to develop Cobalamin oral insulin product

ACCESS PHARMACEUTICALS, INC. signed a collaborative development agreement with bioRASI, LLC, a full-service global CRO specializing in the accelerated development of novel therapeutics, to facilitate clinical development for its Cobalamin™-based oral insulin and other Cobalamin-based products.

31 Mar 2010

Ikaria Holdings acquires NDA and IND application for LUCASSIN drug

Ikaria Holdings, Inc. announced today that it has acquired the New Drug Application (NDA) and the Investigational New Drug (IND) application to LUCASSIN® (terlipressin for injection) from Orphan Therapeutics, assuming all future development and ownership of the drug in North America and Australia.

31 Mar 2010

Hospira acquires Orchid's injectables formulations business

Hospira, Inc., the world leader in generic injectable pharmaceuticals, today announced it has completed the acquisition of the generic injectable pharmaceuticals business of Orchid Chemicals & Pharmaceuticals Ltd., a leading Indian pharmaceuticals company, for approximately $400 million.

31 Mar 2010

Neuroscientists prevent memory loss in fruit flies by blocking activity of PI3 kinase signaling protein

By blocking the cellular signaling activity of a protein, a team of neuroscientists at Cold Spring Harbor Laboratory (CSHL) has prevented memory loss in fruit flies caused by brain plaques similar to those thought to cause Alzheimer's disease in humans. The study also resolves a long-standing controversy about the role of this protein, PI3 kinase, which was previously thought to have a protective function against the disease.

30 Mar 2010

Mood altering effects of Phenytoin

Phenytoin is a well known antiepileptic agent widely used throughout the world. Recent clinical studies in patients with bipolar disorder have suggested that, as for other anticonvulsant drugs commonly used in the treatment of bipolar patients including valproate and carbamazepine, phenytoin may have mood-stabilizing effects in addition to its well-known anticonvulsant properties.

30 Mar 2010

Kun Run Biotechnology's fiscal 2009 fourth-quarter revenues decrease 19%

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China that focuses on manufacturing and sales of peptides and peptide-based drugs, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2009.

30 Mar 2010

Call to ban Miaow-Miaow - Mephedrone

Mephedrone also known as “m-cat” or “miaow-miaow” is a synthetic stimulant drug that has effects similar to amphetamines and ecstasy. Mephedrone use has spread fast in UK since it emerged at a pop festival on the Isle of Wight in July last year.

30 Mar 2010

Britain popping “pills for every ill”, says research

A new study reports that Britons are turning to prescription drugs for every illness, minor or major. This recent paper titled “A Pill for Every Ill”, published in Social Science & Medicine journal says that while two decades earlier average number of prescriptions dispensed per person was only eight, it is more than 16 now.

30 Mar 2010

NHS Primary Care Trust Managers inefficient, says Commons Health Committee report

Managers of NHS primary care trusts (PCTs) who are in charge of 80% of the annual budget have drawn flak recently from the MPs. Figures revealed last week that the number of health managers have risen by 80% in the last decade.

30 Mar 2010

Emory Institute of Drug Discovery and Zirus collaborate to develop new anti-viral drugs

The Emory Institute of Drug Discovery and Zirus, Inc., a biotechnology company based in Buford, Georgia, have entered into a collaboration and research agreement to develop novel compounds to treat infectious disease. Zirus uses a proprietary method for identifying genes and gene products in host cells that, when blocked, can prevent viruses from multiplying. Over the past several years, either alone or in collaboration with partners, including the Centers for Disease Control and Prevention (CDC), Zirus has identified, licensed and filed patents on more than 1000 targets.

30 Mar 2010

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

Sanofi-aventis announced today that the National Institute for Health and Clinical Excellence (NICE) in England and Wales, has just published a new appraisal consultation document for Multaq(R) (dronedarone) indicating its intention to recommend Multaq(R) use for the management of patients with atrial fibrillation.

30 Mar 2010

Preclinical study of DAS181 for treatment and prevention of ILI published

NexBio, Inc. announced today the publication in the Journal of Infectious Diseases of a preclinical study suggesting that treatment with DAS181 (Fludase®) may reduce the risk of secondary bacterial pneumonia following influenza virus infection.

30 Mar 2010

Higher levels of CRP associated with brain changes: Study

New research shows that a high level of C-reactive protein, a marker for inflammation in the blood, is associated with brain changes that are linked to problems with executive thinking skills. The study is published in the March 30, 2010, issue of Neurology®, the medical journal of the American Academy of Neurology.

30 Mar 2010

Research challenges current thinking about TB bacterium

Two new tuberculosis studies by UT Southwestern Medical Center researchers provide good news and bad news about the bacterium that infects nearly a third of the world's population and a disease that kills nearly 2 million people each year.

30 Mar 2010